VTE prophylaxis for the medical patient: where do we stand? – A focus on cancer patients

Thrombosis Research

Volumn 125, Issue , 2010, Pages S21-S29

  Cohen, Alexander T ^a   Nandini, Bharathi ^a   Wills, Jack O ^a   Ota, Satoshi ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cancer; Medical illness; Risk assessment model; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MORPHOLINE DERIVATIVE; POLYSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE; WARFARIN;

HUMAN; NEOPLASM; REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MORPHOLINES; NEOPLASMS; POLYSACCHARIDES; PYRAZOLES; PYRIDONES; THIOPHENES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77955495972     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70008-6     Document Type: Article

References (105)

1. th Edition). Chest 133:6 Suppl (2008), 381S–453S.
2. Lindblad, B, Sternby, NH, Bergqvist, D, Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 302 (1991), 709–711.
3. Sandler, DA, Martin, JF, Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med 82 (1989), 203–205.
4. Cohen, AT, Edmondson, RA, Phillips, MJ, Ward, VP, Kakkar, VV, The changing pattern of venous thromboembolic disease. Haemostasis 26 (1996), 65–71.
5. Sperry, KL, Key, CR, Anderson, RE, Toward a population-based assessment of death due to pulmonary embolism in New Mexico. Hum Pathol 21 (1990), 159–165.
6. Alikhan, R, Peters, F, Wilmott, R, Cohen, AT, Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 57 (2004), 1254–1257.
7. Shojania, KG, Duncan, BW, McDonald, KM, et al. Making health care safer: a critical analysis of patient safety practices. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco Stanford Evidence-based Practice Centre under Contract No. 290–97–0013), July 2001, Agency for Healthcare Research and Quality, Rockville, MD, 332–346 AHRQ Publication No. 01-E058. Available at www.ahrq.gov/clinic/pt-safety/. Accessed January 3, 2002.
8. Samama, MM, Cohen, AT, Darmon, J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341 (1999), 793–800.
9. Leizorovicz, A, Cohen, AT, Turpie, AGG, Olsson, CG, Vaitkus, PT, Goldhaber, SZ, A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004), 874–879.
10. Nicolaides, AN, Fareed, J, Kakkar, AK, et al. Prevention and treatment of venous thromboembolism international consensus statement (guidelines according to scientifi c evidence). Int Angiol 25 (2006), 101–161.
11. Geerts, WH, Heit, JA, Clagett, GP, et al. Prevention of venous thromboembolism. Seventh ACCP Recommendations. Chest 126 (2004), 338S–400S.
12. Anderson, FA Jr, Wheeler, HB, Goldberg, RJ, Hosmer, DW, Forcier, A, Patwardhan, NA, Physician practices in the prevention of venous thromboembolism. Ann Intern Med 115 (1991), 581–585.
13. Ageno, W, Squizzata, A, Ambrosini, F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87 (2002), 746–750.
14. Ahmad, HA, Geissler, A, Maclellan, DG, Deep venous thrombosis prophylaxis: are guidelines being followed?. A NZ J Surg 72 (2002), 331–334.
15. Bergmann, J-F, Mouly, S, Thromboprophylaxis in medical patients: focus on France. Semin Thromb Hemost 28:Suppl 3 (2002), 51–55.
16. Arcelus, JI, Candocia, S, Traverso, CI, Fabrega, F, Caprini, JA, Hasty, JH, Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 17:Suppl 3 (1991), 313–318.
17. Cohen, AT, Tapson, VF, Bergmann, JF, Goldhaber, SZ, Kakkar, AK, Deslandes, B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (2008), 387–394.
18. Emerson, PA, Marks, P, Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. BMJ 1 (1977), 18–20.
19. Handley, AJ, Low-dose heparin after myocardial infarction. Lancet 2 (1972), 623–624.
20. Warlow, C, Beattie, AG, Terry, G, Ogston, D, Kenmure, ACF, Douglas, AS, A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 2 (1973), 934–936.
21. Belch, JJ, Lowe, GDO, Ward, AG, Forbes, CD, Prentice, CRM, Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26 (1981), 115–117.
22. Anderson, GM, Hull, E, The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 39 (1950), 697–702.
23. Kierkegaard, A, Norgren, L, Olsson, C-G, Castenfors, J, Persson, G, Persson, S, Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 222 (1987), 409–414.
24. Donati, MB, Cancer and thrombosis. Haemostasis 24 (1994), 128–131.
25. Falanga, A, Donati, MB, Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 73 (2001), 137–144.
26. Lip, GY, Chin, BS, Blann, AD, Cancer and the prothrombotic state. Lancet Oncol 3 (2002), 27–34.
27. Sutherland, DE, Weitz, IC, Liebman, HA, Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72 (2003), 43–52.
28. Otten, HMMB, Prins, MH, Smorenburg, SM, Hutten, BA, Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 30:Suppl 2 (2000), 72–76.
29. Clarke-Pearson, DL, Synan, IS, Colemen, RE, Hinshaw, W, Creasman, WT, The natural history of postoperative venous thromboemboli in gynaecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 148 (1984), 1051–1054.
30. Marras, LC, Geerts, WH, Perry, JR, The risk of venous thromboembolism is increased throughout the course of malignant glioma. An evidence-based review. Cancer 89 (2000), 640–646.
31. Heit, JA, O'Fallon, WM, Petterson, TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. A population-based study. Arch Intern Med 162 (2002), 1245–1248.
32. Alikhan, R, Cohen, AT, Combe, S, et al., MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164 (2004), 963–968.
33. Cohen, AT, Davidson, BL, Gallus, AS, Lassen, MR, Prins, MH, Tomkowski, W, et al. Efficacy and safety of fondaparinux for the prevention of VTE in older acute medical patients. BMJ 332 (2006), 325–329.
34. Akl, EA, van Doormaal, FF, Barba, M, Kamath, G, Kim, SY, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev(3), 2007.
35. Alikhan, R, Cohen, AT, Combe, S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin:a subgroup analysis of the MEDENOX Study. Blood Coagul Fibrinolysis 14 (2003), 341–346.
36. Cohen, AT, Turpie, AG, Liezorovicz, A, Olsson, CG, Vaitkus, PT, Goldhaber, SZ, Thromboprophylaxis with dalteparin in medical patients: Which patients benefit?. Vasc Med 12 (2007), 123–127.
37. Halkin, H, Goldberg, J, Modan, M, et al. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 96 (1982), 561–565.
38. Heit, JA, Silverstein, MD, Mohr, DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 86 (2001), 452–463.
39. Levine, MN, Gent, M, Hirsh, J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 (1988), 404–407.
40. Saphner, T, Tormey, DC, Gray, R, Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9 (1991), 286–294.
41. Bern, MM, Lokich, JJ, Wallach, SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112 (1990), 423–428.
42. Monreal, M, Alastrue, A, Rull, M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75 (1996), 251–253.
43. Randolph, AG, Cook, DJ, Gonzales, CA, et al. Benefit of heparin in central venous and pulmonary artery catheters. A meta-analysis of randomized controlled trials. Chest 113 (1998), 165–171.
44. Joynt, GM, Kew, J, Gomersall, CD, et al. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest 117 (2000), 178–183.
45. Mian, NZ, Bayly, R, Schreck, DM, et al. Incidence of deep venous thrombosis associated with femoral venous catheterization. Acad Emerg Med 4 (1997), 1118–1121.
46. Levine, M, Hirsh, J, Gent, M, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994), 886–889.
47. Agnelli, G, Gussoni, G, Bianchini, C, Verso, M, Mandalá, M, Cavanna, L, et al., PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:10 (2009), 943–949.
48. Perry, JR, Rogers, L, Laperriere, N, Julian, J, Geerts, W, Agnelli, G, et al., for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol, 25(18S), 2007 Abstract 2011.
49. Haas, SK, Kakkar, AK, Kemkes-Matthes, B, Freund, M, Gatzemeier, U, Heilmann, L, et al. Prevention of Venous Thromboembolism with Low-Molecular-Weight Heparin in Patients with Metastatic Breast or Lung Cancer – Results of the TOPIC Studies. J Thromb Haemost, 3(Suppl 1), 2005 Abstract OR059.
50. Lyman, GH, Khorana, AA, Falanga, A, Clarke-Pearson, D, Flowers, C, Jahanzeb, M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:34 (2007), 5490–5505.
51. Mandala, M, Falanga, A, Piccioli, A, Prandoni, P, Pogliani, EM, Labianca, R, Barni, S, working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59:3 (2006), 194–204.
52. Mandala, M, Falanga, A, Roila, F, ESMO Guidelines Working Group. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol(Suppl 4), 2009, 182–184.
53. Altinbas, M, Coskun, HS, Er, O, Ozkan, M, Eser, B, Unal, A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:8 (2004), 1266–1271.
54. Kakkar, AK, Levine, MN, Kadziola, Z, Lemoine, NR, Low, V, Patel, HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:10 (2004), 1944–1948.
55. Klerk, CP, Smorenburg, SM, Otten, HM, Lensing, AW, Prins, MH, Piovella, F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:10 (2005), 2130–2135.
56. Lazo-Langner, A, Goss, GD, Spaans, JN, Rodger, MA, The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5:4 (2007), 729–737.
57. Kuderer, NM, Khorana, AA, Lyman, GH, Francis, CW, A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:5 (2007), 1149–1161.
58. Griffiths, GO, Burns, S, Noble, SI, Macbeth, FR, Cohen, D, Maughan, TS, FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer, 9, 2009, 355.
59. Buller, H, Prins, MH, J Thromb Haemost, 5(Suppl 2), 2009 LB-MO-004. ISTH abstract.
60. th 2009.
61. ASHP advantage. http://www.improvingpatientoutcomes.com/docs/xxii-handout.pdf. Accessed November 2009.
62. Fraisse, F, Holzapfel, L, Coulaud, J-M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 161 (2000), 1109–1114.
63. Prescott, SM, Richards, KL, Tikoff, G, Armstrong, JD Jr, Shigeoka, JW, Venous thromboembolism in decompensated chronic obstructive pulmonary disease. A prospective study. Am Rev Respir Dis 123 (1981), 32–36.
64. Miehsler, W, Reinisch, W, Valic, E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 53 (2004), 542–548.
65. Haas, S, Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 28 (2002), 577–583.
66. Motykie, GD, Caprini, JA, Arcelus, JI, et al. Risk factor assessment in the management of patients with suspected deep vein thrombosis. Int Angiol 19 (2000), 47–51.
67. Turpie, AGG, Prophylaxis of venous thromboembolism in stroke patients. Semin Thromb Hemost 23 (1997), 155–215.
68. Sandercock, PAG, van den Belt, AGM, Lindley, RI, Slattery, J, Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 56 (1993), 17–25.
69. Schulman, S, Beyth, RJ, Kearon, C, Levine, MN, Clinical Practice Guidelines (8th Edition) American College of Chest Physicians Evidence-Based and Thrombolytic Treatment: Hemorrhagic Complications of Anticoagulant. Chest, 133, 2008, 257 98S.
70. Sherman, DG, Albers, GW, Bladin, C, Fieschi, C, Gabbai, AA, Kase, CS, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369:9570 (2007), 1347–1355.
71. Albers, GW, Amarenco, P, Easton, JD, Sacco, RL, Teal, P, Antithrombotic and Thrombolytic Therapy for Ischemic Stroke – American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:6 suppl (2008), 630S–669S.
72. Adams, HP Jr, Adams, RJ, Brott, T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34 (2003), 1056–1083.
73. Leys, D, Kwiecinski, H, Bogousslavsky, J, Bath, P, Brainin, M, Diener, HC, Kaste, M, Sivenius, J, Hennerici, MG, Hacke, W, EUSI Executive Committee; EUSI Writing Committee. Prevention. European Stroke Initiative. Cerebrovasc Dis 17:Suppl 2 (2004), 15–29.
74. Smeeth, L, Cook, C, Thomas, S, Hall, AJ, et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367 (2006), 1075–1080.
75. Samama, M-M, An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 160 (2000), 3415–3420.
76. Bauer, KA, The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 135 (2001), 367–373.
77. Laffan, M, Tuddenham, E, Assessing thrombotic risk. BMJ 317 (1998), 520–523.
78. Gensini, GF, Prisco, D, Falciani, M, Comeglio, M, Colella, A, Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 23 (1997), 55–67.
79. Abdollahi, M, Cushman, M, Rosendaal, FR, Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89 (2003), 493–498.
80. Goldhaber, SZ, Grodstein, F, Stampfer, MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 277 (1997), 642–645.
81. Leone, G, Sica, S, Chiusolo, P, Teofili, L, de Stefano, V, Blood cell diseases and thrombosis. Haematologica 86 (2001), 1236–1244.
82. Daly, E, Vessey, MP, Hawkins, MM, Carson, JL, Gough, P, Marsh, S, Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996), 977–980.
83. Daly, E, Vessey, MP, Painter, R, Hawkins, MM, Case-control study of venous thromboembolism in users of hormone replacement therapy [letter]. Lancet, 348, 1996, 1027.
84. Grady, D, Wenger, NK, Herrington, D, et al. Postmenopausal hormone replacement therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132 (2000), 689–696.
85. Hulley, S, Furberg, C, Barrett-Connor, E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002), 58–66.
86. Bates, SM, Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 108 (2003), 97–106.
87. Kakkar, VV, Corrigan, TP, Fossard, DP, Prevention of fatal postoperative PE by low doses of heparin: an International Trial. Lancet ii (1975), 45–51.
88. Esquivel, CO, Bergqvist, D, Bjork, C-G, Nilsson, B, Comparison between commercial heparin, LMWH and pentosan polysulphate on haemostasis and platlets in vivo. Thromb Res, 28, 1982, 389.
89. Carter, CJ, Kelton, JG, Hirsh, J, Cerskus, AL, Santos, AV, et al. The relationship between haemorrhagic and antithrombotic properties of LMWH and heparins. Blood, 59, 1982, 1239.
90. Turpie, AGG, Bauer, KA, Eriksson, BI, Lassen, MR, Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 (2002), 1833–1840.
91. Cade, JF, High risk of the critically ill for venous thromboembolism. Crit Care Med 10 (1982), 448–450.
92. Cade, JF, Andrews, JT, Stubbs, AE, Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust NZ J Med 12 (1982), 501–504.
93. Ibarra-Pérez, C, Lau-Cortés, E, Colmenero-Zubiate, S, et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 39 (1988), 505–513.
94. Gåardlund, B, Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 347 (1996), 1357–1361.
95. Mismetti, P, Laporte-Simitsidis, S, Tardy, B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated heparin or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83 (2000), 14–19.
96. Mahe, I, Bergmann, JF, d'Azemar, P, Vaissie, JJ, Caulin, C, Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double-blind study. Eur J Clin Pharmacol 61 (2005), 347–351.
97. Dentali, F, Douketis, JD, Gianni, M, Lim, W, Crowther, MA, Meta-analysis: Anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146 (2007), 278–288.
98. Lechler, E, Schramm, W, Flosbach, CW, THE PRIME Study Group. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 26:Suppl 2 (1996), 49–56.
99. Kleber, F-X, Witt, C, Vogel, G, Koppenhagen, K, Schomaker, U, Flosbach, CW, for THE-PRINCE study group. A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 (2003), 614–621.
100. Hillbom, M, Erilä, T, Sotaniemi, K, Tatlisumak, T, Sarna, S, Kaste, M, Enoxaparin vs heparin for prevention of deep vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 106 (2002), 84–92.
101. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-3: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308 (1994), 235–246.
102. Mazzone, C, Chiodo Grandi, F, Sandercock, P, Miccio, M, Salvo, R, Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database Syst Rev, 18(4), 2004 Oct CD001922.
103. Dennis, M, Rudd, A, Bowler, G, Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 373 (2009), 1958–1965.
104. Kucher, N, Koo, S, Quiroz, R, Cooper, JM, Paterno, MD, Soukoonnikov, B, Goldhaber, SZ, Electronic alerts to prevent venous thromboembolism among hospitalised patients. N Engl J Med 352 (2005), 969–977.
105. Kucher, N., Puck, M, Blaser, J, Bucklar, G, Eschmann, E, Luscher, TF, Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalised medical patients. J Thromb Haemost 7 (2009), 1291–1296.